

**What is Claimed is:**

1. A process for the preparation of a polymorph of 1-[*tert*-butyl-1-*p*-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (1) by crystallization from an alcohol, said process comprising treating a crude 1-[*tert*-butyl-1-*p*-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (1) with ethanol.
2. The process according to claim 1, wherein crude (1) is treated with ethanol at a temperature from 0 °C to 80 °C.
3. The process according to claim 2, wherein 1 part per weight of crude (1) is treated with 2 to 50 parts per weight ethanol.
4. A process for the preparation of a polymorph of 1-[*tert*-butyl-1-*p*-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (1) by crystallization from an alcohol, said process comprising:
  - (a) dissolving crude (1) with ethanol,
  - (b) adding seeding crystals of the pure polymorph of (1),
  - (c) allowing the pure polymorph of (1) to crystallize,
  - (d) adding water until the crystallization is almost completed,
  - (e) separating of the pure polymorph of (1), and
  - (f) optionally washing the resulting pure polymorph of (1) with water and drying at elevated temperature and/or *in vacuo*.
5. A process for the preparation of a polymorph of 1-[*tert*-butyl-1-*p*-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (1) by crystallization from an alcohol, said process comprising:
  - (i) treating 1.01-1.1 mole of 4-amino—1-(2-morpholinoethoxy)naphthalene (2) with 1 mole of 5-(2,2,2-trichloroethoxycarbonyl)amino-3-*tert*-butyl-1-*p*-tolylpyrazole (3) in the presence of 1 mole of a secondary amine and a solvent consisting of DMSO and ethyl acetate to produce crude (1);

- (ii) isolating crude (1);
- (iii) washing crude (1) with ethyl acetate and
- (iv) treating the residue with ethanol.

5            6.        The process according to any one of claims 1, 4 or 5, wherein the pure polymorph of (1) is characterized by the following X-ray powder diffractogram (XRPD), which is analyzed using an X-Ray Powder Diffractometer utilizing CuK $\alpha$  radiation ( $\lambda=1.5418\text{\AA}$ ), run at 40kV, 30mA:

Peak Position ( $^{\circ}2\theta$ )	Relative Intensity	d-Space ( $\text{\AA}$ )
5.4	38	16.4
7.0	14	12.7
8.9	46	9.90
10.4	66	8.54
10.7	7	8.31
11.5	17	7.68
12.6	7	7.05
13.8	50	6.41
14.3	100	6.18
15.5	7	5.71
15.9	9	5.58
16.5	17	5.38
17.1	75	5.19
18.2	19	4.87
18.7	19	4.76
19.1	39	4.65
20.0	32	4.45
20.7	79	4.29
21.0	45	4.24
21.7	35	4.09
22.8	47	3.90
23.3	28	3.82
23.8	33	3.73
24.7	26	3.60
25.1	26	3.55
25.8	22	3.45
26.3	21	3.39
26.4	21	3.37
26.6	20	3.35
26.8	16	3.33
28.0	15	3.19
28.4	16	3.14

29.8	9	2.99
31.6	9	2.83
32.9	16	2.72
34.0	12	2.64

7. An essentially pure product polymorph of 1-[*tert*-butyl-1-p-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (1) produced by the process according to claims 1, 4, 5 or 6.

5

8. A pharmaceutical composition comprising a pharmaceutically effective amount of the polymorph Form 1 of (1) according to claim 7 in combination with at least one pharmaceutical excipient.

10

9. A method of treating an inflammatory disease which comprises administering to a patient a therapeutically effective amount of a polymorph of (1) according to claim 7.